Abstract:Background: Tolerogenic dendritic cells (DCs) offer promising prospects as cell-based treatment for autoimmune diseases, including systemic lupus erythematosus (SLE). However, the precise mechanisms accounting for tolerogenic DCs mediated immunoregulation in SLE remain incompletely understood. Objectives: We previously identified tolerogenic CD1c+DCs played important roles in mesenchymal stem cells transplantation treatment for SLE. Here we further investigate the immunoregulatory effect of CD141+DCs in the pathogenesis of lupus. Methods: A total of 12 SLE patients and 12 age-matched and gender-matched healthy subjects were included in the study. The number and percentage of peripheral blood CD141+DCs and their expression of functional costimulatory markers (CD40, CD80, CD83, and CD86) were compared between SLE patients and healthy controls. Moreover, the tolerogenic property of CD141+DCs and CD1c+DCs were compared by stimulating with LPS or SLE serum. Results: Our research revealed the number of peripheral CD141+DCs decreased in lupus, which was negatively correlated with SLE disease activity index score. Moreover, CD141+DCs in SLE patients exhibited distinct tolerogenic properties by decreasing expression of CD40, CD80, CD86 compared with healthy controls. Furthermore, CD141+DCs exhibited superior tolerogenicity compared to CD1c+DCs in SLE, by reducing expression of CD86 and reducing production of TNFα. Conclusion: CD141+DCs may play a more significant role than the commonly studied CD1c+DCs in ameliorating immune dysfunction and maintaining immune homeostasis in SLE. Our findings contribute to a better understanding of the immunoregulatory mechanisms underlying SLE and pave the way for novel therapeutic approaches targeting CD141+DCs. REFERENCES: [1] Yuan X, Qin X, Wang D, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients. Nat Commun. 2019;10(1):2498. [2] Chu CC, Ali N, Karagiannis P, et al. Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med. 2012;209(5):935-945. [3] Comi M, Avancini D, Santoni de Sio F, et al. Coexpression of CD163 and CD141 identifies human circulating IL-10-producing dendritic cells (DC-10). Cell Mol Immunol. 2020;17(1):95-107. [4] Sachamitr P, Leishman AJ, Davies TJ, Fairchild PJ. Directed Differentiation of Human Induced Pluripotent Stem Cells into Dendritic Cells Displaying Tolerogenic Properties and Resembling the CD141+ Subset. Front Immunol. 2018;8:1935. [5] Worbs T, Hammerschmidt SI, Förster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17(1):30-48. [6] Adamik J, Munson PV, Hartmann FJ, et al. Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells. Nat Commun. 2022;13(1):5184. [7] Breton G, Lee J, Zhou YJ, et al. Circulating precursors of human CD1c+ and CD141+ dendritic cells. J Exp Med. 2015;212(3):401-413. Acknowledgements: NIL. Disclosure of Interests: None declared.

Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Pd-1(+)Cxcr5(-)Cd4(+)T Cells Are Correlated With The Severity Of Systemic Lupus Erythematosus

Aberrant CD200/CD200R1 Expression and Function in Systemic Lupus Erythematosus Contributes to Abnormal T-cell Responsiveness and Dendritic Cell Activity

Abnormalities in Circulating Plasmacytoid Dendritic Cells in Patients with Systemic Lupus Erythematosus.

Abnormal Expression of Cd43 in Patients with Systemic Lupus Erythematosus and Its Clinical Significance

Peripheral CD24hi CD27+ CD19+ B Cells Subset As a Potential Biomarker in Naïve Systemic Lupus Erythematosus.

[Clinical Significance of CD4+CD25+ T Cells in Peripheral Blood of Patients in Systemic Lupus Erythematosus].

Correlation between levels of dendritic cell subsets in systemic lupus erythematosus patients and SLEDAI

Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells

Elevated Apoptosis and Impaired Proliferation Contribute to Downregulated PeripheralγδT Cells in Patients with Systemic Lupus Erythematosus

Frequency and Significance of CD4+CD25+T Cell Subpopulations in the Peripheral Blood of Patients with Systemic Lupus Erythematosus

Decreased CD1d level is associated with CD86 over-expression in B cells from systemic lupus erythematosus.

The relationship between the frequency of dendritic cell subsets in peripheral blood and kidney damage in patients with systemic lupus erythematosus

AB1118 HUMAN CD141+ DENDRITIC CELLS (dcs) REPRESENT A UNIQUE TOLEROGENIC DC SUBSET THAT INDUCE IMMUNE-TOLERANCE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Study of the expression of interleukin-12 and interferon-α and their relationships with the dendritic cell subsets in systemic lupus erythematosus patients

Distinct Roles of Myeloid and Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus

Dendritic Cells in Systemic Lupus Erythematosus: from Pathogenic Players to Therapeutic Tools.

TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.

Elevated Circulating Cd4(+)Icos(+)Foxp3(+) T Cells Contribute to Overproduction of Il-10 and Are Correlated with Disease Severity in Patients with Systemic Lupus Erythematosus